Company profile for Priovant Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Priovant Therapeutics is a biotechnology company dedicated to developing innovative therapies for autoimmune and inflammatory diseases. Leveraging cutting-edge science and advanced therapeutic approaches, we focus on creating targeted treatments that address significant unmet medical needs in these challenging disease areas. Our mission is to improve the lives of patients by delivering safe, effective, and transformative thera...
Priovant Therapeutics is a biotechnology company dedicated to developing innovative therapies for autoimmune and inflammatory diseases. Leveraging cutting-edge science and advanced therapeutic approaches, we focus on creating targeted treatments that address significant unmet medical needs in these challenging disease areas. Our mission is to improve the lives of patients by delivering safe, effective, and transformative therapies that offer hope and better health outcomes. At Priovant Therapeutics, we are committed to advancing healthcare through innovation, research, and patient-centered solutions.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1007 Slater Road Suite 250 Durham, NC 27703
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://investor.roivant.com/news-releases/news-release-details/roivant-and-priovant-announce-positive-phase-3-valor-study

PRESS RELEASE
17 Sep 2025

https://www.globenewswire.com/news-release/2025/06/09/3096179/34323/en/Roivant-and-Priovant-to-Host-Investor-Video-Conference-at-1-00-PM-ET-on-Tuesday-June-17-on-Brepocitinib-and-the-Unmet-Medical-Need-in-Dermatomyositis.html

GLOBENEWSWIRE
09 Jun 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty